verapamil has been researched along with Diseases, Metabolic in 5 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil was most active as a vasodilator in muscular microvasculature." | 1.27 | Pharmacologic inhibition of cerebral vasospasm in ischemia, hallucinogen ingestion, and hypomagnesemia: barbiturates, calcium antagonists, and magnesium. ( Altura, BM; Altura, BT, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, HW | 1 |
| Park, H | 1 |
| Semple, IA | 1 |
| Jang, I | 1 |
| Ro, SH | 1 |
| Kim, M | 1 |
| Cazares, VA | 1 |
| Stuenkel, EL | 1 |
| Kim, JJ | 1 |
| Kim, JS | 1 |
| Lee, JH | 1 |
| Czaja, MJ | 1 |
| Clark, AG | 1 |
| Altura, BM | 1 |
| Altura, BT | 1 |
| Reines, E | 1 |
| Johnsen, A | 1 |
| Husum, D | 1 |
| Jensen, G | 1 |
1 review available for verapamil and Diseases, Metabolic
| Article | Year |
|---|---|
[Verapamil poisoning. A case with fatal course and literature review].
Topics: Central Nervous System Diseases; Heart Block; Humans; Hypotension; Male; Metabolic Diseases; Middle | 1987 |
4 other studies available for verapamil and Diseases, Metabolic
| Article | Year |
|---|---|
Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers.
Topics: Animals; Autophagy; Calcium; Calcium Channel Blockers; Cytosol; Echocardiography; Hep G2 Cells; Hepa | 2014 |
A new mechanism of lipotoxicity: Calcium channel blockers as a treatment for nonalcoholic steatohepatitis?
Topics: Animals; Autophagy; Calcium Channel Blockers; Humans; Lysosomes; Metabolic Diseases; Obesity; Phagos | 2015 |
Metabolic Diseases World Summit 2005. Partnering and deal-making. 29 June-1 July 2005, San Francisco, CA, USA.
Topics: Biotechnology; Drug Industry; Humans; Metabolic Diseases; Receptor, Melanocortin, Type 4; Verapamil | 2005 |
Pharmacologic inhibition of cerebral vasospasm in ischemia, hallucinogen ingestion, and hypomagnesemia: barbiturates, calcium antagonists, and magnesium.
Topics: Animals; Barbiturates; Brain Ischemia; Calcium Channel Blockers; Cerebral Arteries; Magnesium; Metab | 1983 |